NCT03645928Phase 2Terminated

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Study sponsor: Iovance Biotherapeutics, Inc. · IOVA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-02-20Actual
Enrollment · participants225Actual
Source updated2026-05-15Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 6 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Objective Response Rate Measure: Safety Profile Measured by Grade ≥3 TEAEs Measure: To evaluate the feasibility of producing lifileucel using tumor samples obtained before (Cohort 3D) or during (Cohort 3E) frontline platinum doublet chemotherapy and pembrolizumab in patients with Stage IV NSCLC. After: Measure: Objective Response Rate Measure: Safety Profile Measured by Grade ≥3 TEAEs Measure: Percentage of patients for whom lifileucel is successfully manufactured and meets release specification.

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 245 participants (planned). After: 225 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 9 Aug 2029. After: 20 Feb 2026.

Recruitment status changed

Before: Recruiting. After: Terminated.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview